Judith del Campo

Judith del Campo

Auto-generated profile, based on publicly available information

Judith del Campo

Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in Methods
Verified
Journal Article
Closed access
JCJudith del Campo
Judith del Campo
CZCaridad Zayas
Caridad Zayas
Belkis RomeuBelkis Romeu
Belkis Romeu
RAReinaldo Acevedo
Reinaldo Acevedo
EGElizabeth González
Elizabeth González
MLMiriam Lastre
Miriam Lastre

1 April 2006 in Vaccine
Verified
Journal Article
Closed access
JCJudith del Campo
Judith del Campo
MLMiriam Lastre
Miriam Lastre
GBGustavo Bracho
Gustavo Bracho
TRTamara Rodríguez
Tamara Rodríguez
DGDanay Gil
Danay Gil
OPOliver Pérez
Oliver Pérez

1 March 2011 in Canadian Journal of Microbiology
Verified
Journal Article
Closed access
Belkis RomeuBelkis Romeu
Belkis Romeu
EGElyzabeth González
Elyzabeth González
JCJudith del Campo
Judith del Campo
RAReynaldo Acevedo
Reynaldo Acevedo
CZCaridad Zayas
Caridad Zayas
OPOliver Pérez
Oliver Pérez
Mucosal immune responses are an early and important line of defense against pathogens. The current understanding of the mucosal immune system allows us to consider the use of nasal immunization for induction of antigen-specific immune responses at the mucosal surface and the systemic compartment. Mucosal adjuvants are key for developing novel mucosal vaccines and represent 1 approach to improving mucosal and systemic immunity. However, few mucosal vaccine adjuvants are currently approved for human use. Neisseria meningitidis B proteoliposome-derived cochleate (AFCo1 — Adjuvant Finlay Cochleate 1) has been demonstrated to be a potent mucosal adjuvant. The present work demonstrates that intranasal immunization of 3 doses of tetanus toxoid (TT) coadministered with AFCo1 in mice promotes high systemic and mucosal responses. The anti-TT IgG serum titers and the mucosal anti-TT IgA in saliva and vaginal wash were significantly higher than TT alone. The analysis of antibody subclasses showed that intranasal administration of AFCo1 + TT induced not only IgG1 but also IgG2a anti-TT antibodies at levels comparable to those obtained with TT vaccine (vax-TET). These data support the fact that AFCo1 is a potent mucosal adjuvant in nasal immunization to a coadministered protein antigen.